Search Results

You are looking at 1 - 3 of 3 items for

  • Author: Manuela Mihalache x
Clear All Modify Search
Open access

Maria Rotaru, Gabriela Iancu, Manuela Mihalache, Gabriela Anton and Silviu Morariu

Abstract

Background. Medical research has shown a continuous increase in the incidence of skin cancers, especially among young individuals. One of the ethiopathogenic factors that cause skin carcinogenesis could be the infection with some genotypes of human papillomavirus (HPV). Methods. In our study, we have analyzed alpha (α) - HPV positivity and HPV genotypes identified in melanocytic (MSC) and nonmelanocytic skin cancers (NMSC). The results were then compared with results obtained from the control group. The study included 40 cases of MSC and NMSC found in the data base of our hospital, and 40 healthy patients. In all of the cases, we identified the HPV DNA by using polymerase chain reaction (PCR), and the viral genotypes by using α -HPV primers by Linear Array Roche kit. Results. The average α-HPV positivity in tumors was 32.50%, higher than in other studies published to date. The squamous cell carcinoma (SCC) lot had the highest α-HPV positivity (40%), followed by basal cell carcinoma (BCC) (35%) and malignant melanoma (MM) (20%). The comparative analysis between skin cancer-HPV positive (32.50%) and the control group-HPV positive (15%) revealed a positivity of HPV in the tumors group (32.50%) that was higher by a ratio of 2.16. By viral genotyping, we identified high-risk HPV only in BCC and MM (in all α-HPV samples), but not in SCC samples. Conclusions. In our study, α-HPV in NMSC and MSC was positive in 32.50% of the cases; in 46.15% of these, it was possible to identify HPV genotypes. The high-risk HPV genotypes observed in these patients were HPV 16, 35, 58 and 59.

Open access

Ariela Ligia Olteanu, Romeo-Gabriel Mihăilă and Manuela Mihalache

Abstract

Introduction: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN), polycytemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), are prone to develop thrombotic events. We aimed to investigate the coagulation status in their plasma using thrombin generation assay (TGA), a functional global assay, on Ceveron® Alpha.

Materials and methods: The samples were collected from 89 consecutive Ph-negative MPN patients and from 78 controls into K2EDTA and CTAD tubes for blood cell counts, TGA and coagulation screening tests. Thrombin generation was analysed in platelet-poor plasma using Technothrombin® TGA assay kit.

Results: We found a significantly increased peak thrombin generation (p=0.049) and velocity index (VI) (p=0.012) in patients in comparison with controls, especially in ET patients, and a significantly higher values for peak thrombin (p=0.043) and VI (p=0.042) in patients receiving anagrelide in comparison with those treated with hydroxyurea. We also noticed an inverse correlation between the length of cytoreductive therapy and TGA parameters, (peak thrombin R=-0.25, p=0.018, AUC R=-0.257, p=0.015, and VI R=-0.21, p=0.048).

Conclusion: Our results suggest that Ph-MPN patients, and especially those with ET, are predisposed to thrombotic events due to their higher peak thrombin and VI values and their risk may decreases as treatment is longer. Patients treated with hydroxyurea generate less thrombin and could be less prone to develop thrombotic events in comparison with those treated with anagrelide.

Open access

Ariela-Ligia Olteanu, Romeo-Gabriel Mihaila, Alina-Camelia Catana, Ofelia Flucus, Cristina Bus and Manuela Mihalache

Abstract

Introduction: Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN): polycythemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF) are characterized by an increased rate of thrombosis complications partly due to platelets activation. Large platelets are more active, have an enhanced procoagulant function and have a pathogenic role in arterial and venous thrombosis. In our study we tried to establish if platelet volume indices (MPV, PDW, P-LCR) issued from automated complete blood count determination are significantly different in Ph-MPN patients in comparison to healthy subjects. Materials and methods: Blood cell counts including platelet volume indices were assessed for 102 Ph-MPN and 102 healthy subjects using the impedance method on Sysmex XS 1000i and glucose and lipid profile, were assessed on Architect c 8000. Assessement of JAK2V617 positivity was conducted with amplification refractory mutation system polymerase chain reaction (ARMS-PCR), in whole peripheral blood. Results: Platelet volume indices (PVI) measured with the impedance based method, did not show significant differences in Ph-MPN patients in comparison to healthy controls. We noticed a moderate correlation between these indices and the presence of JAK2V617F mutation. PVI were increased in the small subgroup of patients treated with anagrelide and decreased in patients treated with simvastatin, comparatively with untreated patients. Conclusion: In our study we did not find a significant difference between platelet volume indices from Ph-MPN patients and healthy subjects. Further studies are required to demonstrate correlations between platelet volume indices and JAK2 V617F mutation, treatment with anagrelide and statins, respectively